FRANKFURT, Oct 25 (Reuters) - German pharmaceutical company Ratiopharm has published an outlook on its earnings for the first time ever as it seeks to attract potential buyers for its business, according to German daily Financial Times Deutschland.
By 2014, the company expects its earnings before interest, tax, depreciation and amortization (EBITDA) to grow by about 20 percent per year, to 530 million euros ($795.3 million), its Chief Executive Oliver Windholz told Financial Times Deutschland in an interview to be published on Monday.
Sales at the world's fourth-largest generic drugs maker will grow by an average of 8 percent per year to 2.4 billion euros by 2014, he said.
Ratiopharm is part of the heavily indebted empire built up by German billionaire Adolf Merckle, who killed himself in January after being forced to cede control of his conglomerate to lenders after huge trading losses.
Ratiopharm's owner, the indebted Merckle group, last month launched the sale of the world's fourth-largest generic drugs maker, saying it hoped to be able to divest the business in one piece given the high number of suitors it expected.
Teva, Sanofi-Aventis and Mylan are tipped as potential suitors for Ratiopharm in the deal, which is being managed by Commerzbank and Royal Bank of Scotland.
This year, Ratiopharm expects to have EBITDA of 200 million euros, with sales of 1.6 billion euros, Financial Times Deutschland said.
(Reporting by Maria Sheahan; Editing by Diane Craft) ($1=.6664 Euro) Keywords: RATIOPHARM/ (maria.sheahan@thomsonreuters.com; +49 69 7565 1286; Reuters Messaging: maria.sheahan.thomsonreuters.com@thomsonreuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
By 2014, the company expects its earnings before interest, tax, depreciation and amortization (EBITDA) to grow by about 20 percent per year, to 530 million euros ($795.3 million), its Chief Executive Oliver Windholz told Financial Times Deutschland in an interview to be published on Monday.
Sales at the world's fourth-largest generic drugs maker will grow by an average of 8 percent per year to 2.4 billion euros by 2014, he said.
Ratiopharm is part of the heavily indebted empire built up by German billionaire Adolf Merckle, who killed himself in January after being forced to cede control of his conglomerate to lenders after huge trading losses.
Ratiopharm's owner, the indebted Merckle group, last month launched the sale of the world's fourth-largest generic drugs maker, saying it hoped to be able to divest the business in one piece given the high number of suitors it expected.
Teva, Sanofi-Aventis and Mylan are tipped as potential suitors for Ratiopharm in the deal, which is being managed by Commerzbank and Royal Bank of Scotland.
This year, Ratiopharm expects to have EBITDA of 200 million euros, with sales of 1.6 billion euros, Financial Times Deutschland said.
(Reporting by Maria Sheahan; Editing by Diane Craft) ($1=.6664 Euro) Keywords: RATIOPHARM/ (maria.sheahan@thomsonreuters.com; +49 69 7565 1286; Reuters Messaging: maria.sheahan.thomsonreuters.com@thomsonreuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.